FOR IMMEDIATE RELEASE
High Hawk Global Announces Strategic Partnership with Genis to Accelerate U.S. and International Expansion
Boston, MA —12/16/2025 — High Hawk Global, a commercialization and strategic growth consultancy specializing in medical technologies and life science innovations, today announced a new partnership with Genis hf., an Iceland-based biotechnology company developing regenerative solutions derived from marine byproducts. The collaboration will support Genis as it scales its global operations and establishes a strong foothold in the U.S. market.
Genis’s flagship consumer product, Benecta™, is a natural dietary supplement produced in Iceland and sold across Europe. Benecta is derived from short-chain chitosan, a unique, bioactive ingredient originating from naturally aged crustacean deposits—primarily shrimp. The supplement has been shown to support individuals experiencing stiffness, aches, lethargy, joint discomfort, and related mobility challenges.
As part of the new partnership, Stephen DiBiasio, Founder and Managing Partner of High Hawk Global, will serve as Chief Operating & Commercialization Advisor to Genis. With more than 30 years of global medical device and life sciences experience, DiBiasio will guide commercialization strategy, operational planning, and U.S. market expansion.
“Genis is advancing impressive science with the potential to help people worldwide,” said Stephen DiBiasio. “Our work together will focus on the U.S. launch of Benecta, as well as the development and commercialization strategies for a pipeline of medical device products based on short-chain chitosan. This includes innovations for oral grafting, orthopedic procedures, and other regenerative applications. Bringing these technologies to market requires scientific alignment, disciplined commercial planning, and a strong go-to-market framework—all of which we’re excited to help build.”
High Hawk Global will work alongside Michael Beaudry, who joins Genis as Head of U.S. Sales & Marketing, to establish the commercial infrastructure, brand positioning, and market education necessary for Benecta’s U.S. introduction. In parallel, the teams will advance long-term planning for medical device products currently in development.
“We are thrilled to welcome High Hawk Global as a strategic partner,” said Sesselja Ómarsdóttir, CEO of Genis. “Stephen, Michael, and the High Hawk team bring extensive expertise in global commercialization, operational scale-up, and strategic execution. Their support will be invaluable as Genis enters its next phase of growth and brings its science to new markets.”
The partnership underscores High Hawk Global’s mission to support pioneering life science and med-tech innovators in achieving sustainable global growth.
About Genis
Genis hf. is an Icelandic biotechnology company developing regenerative solutions from marine byproducts through advanced research and proprietary processing technologies. Its consumer and clinical pipeline includes Benecta™, a natural dietary supplement, and multiple chitosan-based medical technologies designed to support healing, tissue regeneration, and overall well-being.
About High Hawk Global
High Hawk Global is a strategic consulting firm specializing in commercialization, growth strategy, and global expansion for medical device, biotech, and life sciences innovators. With deep experience building and scaling companies worldwide, High Hawk Global partners with high-impact organizations to accelerate market entry, operational readiness, and long-term commercial success.